Detalhe da pesquisa
1.
The Effect of The Oral Iron Chelator Deferiprone on Iron Overload and Oxidative Stress in Patients with Myelodysplastic Syndromes A Study by the Israeli MDS Working Group.
Acta Haematol
; 2023 Dec 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38104534
2.
Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis.
Ann Hematol
; 101(4): 755-762, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35083525
3.
Kinetics of pre-myelodysplastic syndromes blood values correlate with disease risk and survival.
Hematol Oncol
; 38(5): 782-791, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32632931
4.
Can bone marrow cellularity help in predicting prognosis in myelodysplastic syndromes?
Eur J Haematol
; 101(4): 502-507, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-29956845
5.
Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
Br J Haematol
; 178(5): 709-718, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28589704
6.
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.
Ann Hematol
; 95(11): 1811-8, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27546027
7.
Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.
Am J Hematol
; 88(2): 130-4, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23345248
8.
Raising the standards of patient-centered outcomes research in myelodysplastic syndromes: Clinical utility and validation of the subscales of the QUALMS from the MDS-RIGHT project.
Cancer Med
; 12(6): 7529-7539, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36533415
9.
Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?
Cancers (Basel)
; 15(13)2023 Jul 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37444582
10.
MDS-Related Anemia Is Associated with Impaired Quality of Life but Improvement Is Not Always Achieved by Increased Hemoglobin Level.
J Clin Med
; 12(18)2023 Sep 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37762806
11.
Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience.
Leuk Lymphoma
; 62(1): 118-124, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32981410
12.
Thrombotic thrombocytopenic purpura following terbinafine therapy.
J Clin Apher
; 30(1): 58-9, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25255772
13.
Peripheral Blood Cell Mitochondrial Dysfunction in Myelodysplastic Syndrome Can Be Improved by a Combination of Coenzyme Q10 and Carnitine.
Mediterr J Hematol Infect Dis
; 12(1): e2020072, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33194146
14.
Vanishing bile duct syndrome in a patient with multiple myeloma treated with bortizomib, lenalidomide and dexamethasone.
Clin Res Hepatol Gastroenterol
; 47(8): 102198, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37598809
15.
Incidence of Profound Hypogammaglobulinemia and Infection Rate in Lymphoma Patients Following the Combination of Chemotherapy and Rituximab.
Recent Pat Anticancer Drug Discov
; 11(2): 228-35, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26825174
16.
Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome.
Clin Lymphoma Myeloma Leuk
; 15(6): e95-9, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25819366
17.
The May-Hegglin anomaly.
Eur J Haematol
; 83(4): 390, 2009 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-19500132
18.
Safety and efficacy of ibrutinib in a patient with severe renal impairment.
Hematol Rep
; 9(3): 7078, 2017 Sep 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29071051
19.
Second hematologic malignancies in hairy cell leukemia: report of two patients with dynamic mutations in the BRAF gene.
Leuk Lymphoma
; 56(3): 823-5, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25029639
20.
Advantage of MIDAM protocol in treatment of elderly patients with refractory and relapsing acute myeloid leukemia.
J Clin Oncol
; 28(7): e115-6; author reply e117-8, 2010 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20100951